When was GondolaBio founded?

GondolaBio was founded in 2024.

Where is GondolaBio located?

GondolaBio is headquartered in Palo Alto, United States.

Is GondolaBio a funded company?

GondolaBio is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does GondolaBio rank among its competitors?

GondolaBio ranks 640th amongst 1254 active competitors, of which 70 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Johnson & Johnson, which secured $34M in Feb, 2025.

Who are the top competitors of GondolaBio?

GondolaBio's top competitors include AbbVie, Amgen and Gilead. Among them, Johnson & Johnson secured the most recent funding round in February, 2025.

GondolaBio - 2026 Company Profile & Competitors

Most viewed in 2019

GondolaBio is an unfunded company based in Palo Alto (United States), founded in 2024. It operates as a GondolaBio Website. GondolaBio has not raised any funding yet. The company has 1254 active competitors, including 70 funded and 150 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.

Key Metrics

Founded Year

2024

Location

Palo Alto, United States

Stage

Unfunded

Ranked

640^th among 1254 active competitors

Similar Companies

AbbVie & 1280 more

View GondolaBio's full profile

GondolaBio has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GondolaBio include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of GondolaBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Black Capital Investments, Alcor Fund & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Gershon Capital & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Temasek & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, Castle Investment Management ... & 16 others	76/100
6th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
7th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Black Capital Investments, Alcor Fund & 16 others	73/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 7 others	72/100
9th	Novartis 1996, Basel (Switzerland), Public	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, MT Capital & 9 others	70/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	SoftBank Group, MT Capital & 10 others	70/100
640th	GondolaBio 2024, Palo Alto (United States), Unfunded	GondolaBio Website	-	-	16/100